Clinical Trial Update: Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of Radium-223 dichloride in patients with advanced skeletal metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Neoplasm Metastasis | Phase 1 | Status: COMPLETED